AbbVie's $10.9B Apogee deal funded with debt, preserving dividend streak

AbbVie will fund its $10.9 billion acquisition of Apogee Therapeutics with debt, preserving cash reserves and the company's dividend program.

The deal, announced June 22, adds zumilokibart, an investigational treatment for eczema, to AbbVie's immunology pipeline. The company ended 2025 with $17.8 billion in free cash flow.

AbbVie is a Dividend King with 50-plus consecutive years of dividend increases, counting its tenure under Abbott Laboratories. The company's largest acquisition — the $63 billion Allergan purchase in May 2020 — did not disrupt payouts. Dividends have risen 46.6% since that deal closed, a precedent that supports management's commitment to the dividend streak through large transactions.

The debt-funded structure leaves AbbVie's cash balance intact, addressing investor concerns that the $10.9 billion outlay could pressure the payout. Zumilokibart, if approved, could help drive revenue and earnings growth, strengthening the business and supporting the dividend program over the long term.

Skyrizi and Rinvoq, AbbVie's two biggest growth drivers, continue to post strong financial results, helping the company move beyond the Humira patent cliff. Pipeline candidates in the fast-growing weight loss market, where competitors include Novo Nordisk and Eli Lilly, offer additional long-term revenue potential.

For income-focused investors, the deal structure reduces near-term dividend risk. The next catalyst will be AbbVie's third-quarter 2026 earnings report, where management is expected to provide updated guidance on leverage targets and capital allocation priorities.

This article is for informational purposes only and does not constitute investment advice.